26 May, 2017
Alexandria Capital Llc sold 3,350 shares as Regeneron Pharmaceuticals (REGN)'s stock rose 21.24%.
More notable recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Barrons.com which released: "The Hot Stock: Regeneron Pharmaceuticals Soars 6.7%" on May 04, 2017, also Nasdaq.com with their article: "Regeneron Pharmaceuticals Reaches Analyst Target Price" published on May 05, 2017, Fool.com published: "Is Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce?" on May 12, 2017. It is positive, as 48 investors sold REGN shares while 151 reduced holdings.
The share price of the company (NASDAQ:REGN) was up +0.08% during the last trading session, with a high of 464.25 and the volume of Regeneron Pharmaceuticals, Inc. shares traded was 573858. Tarbox Group stated it has 0% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Old Mutual Global Investors UK Ltd. boosted its stake in Regeneron Pharmaceuticals by 137.8% in the third quarter. WI now owns 5,392 shares of the biopharmaceutical company's stock worth $2,168,000 after buying an additional 2,007 shares during the last quarter. Leerink Swann maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Monday, April 4. Polen Capital Management LLC now owns 1,340,649 shares of the biopharmaceutical company's stock worth $492,139,000 after buying an additional 529,348 shares during the last quarter. Live Your Vision LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $157,000. The Fagan Associates Inc holds 2,835 shares with $1.04 million value, up from 1,765 last quarter. WFG Advisors LP increased its stake in shares of Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. Pictet Asset Mgmt Limited owns 312,333 shares for 0.43% of their portfolio. Institutional investors and hedge funds own 68.83% of the company's stock. Blenheim Capital Management BV bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $160,000. Forward Management Llc acquired 192,500 shares as Farmland Partners Inc (FPI)'s stock declined 10.49%. In taking a look at the company's valuation, the firm's price to earnings ratio stands at N/A.
Regeneron Pharmaceuticals, Inc. has a 50 day moving average of 403.99 and a 200 day moving average of 383.98. Hudock Gru Ltd Liability Corporation reported 0.02% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Regeneron Pharmaceuticals also was the target of unusually large options trading activity on Tuesday. Schlumberger N.V. Common Stock has a market cap of 99.64B and has seen an average daily volume of 6987060 over the past three months.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down 1.52% during trading on Wednesday, hitting $454.38. The biopharmaceutical company reported $2.92 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.42. The company's quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter a year ago, the business earned $2.57 EPS.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 4th. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since May 24, 2016 and is uptrending. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of USA and global trademark & copyright law. The original version of this piece can be read at https://transcriptdaily.com/2017/05/25/regeneron-pharmaceuticals-inc-regn-stake-cut-by-baird-financial-group-inc.html.
Several research analysts have recently commented on REGN shares. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has "Neutral" rating given on Thursday, February 16 by Goldman Sachs. Regeneron Pharmaceuticals presently has an average rating of "Hold" and an average price target of $432.21.
02/09/2017 - Regeneron Pharmaceuticals, Inc. had its " rating reiterated by analysts at Credit Suisse. Finally, Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals to $410.00 in a research note on Friday, February 10th. Out of 3 Wall Street analysts rating Inteliquent, 2 give it "Buy", 1 "Sell" rating, while 0 recommend "Hold".
Stock has got outperform rating from 4 analysts of Thomson Reuters whereas 11 analysts given hold rating to the stock.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,000 shares of the firm's stock in a transaction on Wednesday, March 29th. Tracking the stock price relative to moving averages and highs and lows for the year may help evaluate the future value of the stock. Following the sale, the director now directly owns 1,000 shares of the company's stock, valued at approximately $400,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
In related news, Director Michael S. Brown sold 3,000 shares of the company's stock in a transaction dated Friday, May 12th. BAKER CHARLES A sold $1.18M worth of stock.
Lumina Fund Management Llc, which manages about $805.90 million and $946.70 million US Long portfolio, decreased its stake in Select Sector Spdr Tr (XLE) by 115,500 shares to 49,200 shares, valued at $3.71M in 2016Q4, according to the filing. The disclosure for this sale can be found here.
Regeneron Pharmaceuticals, Inc.is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
